PubMed

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.

Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K.

Diabetes Care. 2003 Sep;26(9):2493-9.PMID: 12941708 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.

Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M.

Diabetes. 2004 Jun;53(6):1621-9. Erratum in: Diabetes. 2005 Feb;54(2):587. PMID: 15161771 [PubMed - indexed for MEDLINE]Related articlesFree article

The ratio of leptin to adiponectin can be used as an index of insulin resistance.

Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, Itoh M.

Metabolism. 2008 Feb;57(2):268-73.PMID: 18191059 [PubMed - indexed for MEDLINE]Related articles

Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.

Olansky L, Marchetti A, Lau H.

Clin Ther. 2003;25 Suppl B:B64-80. Review.PMID: 14553867 [PubMed - indexed for MEDLINE]Related articles

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.

Metabolism. 2008 Nov;57(11):1552-7.PMID: 18940393 [PubMed - indexed for MEDLINE]Related articles

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T.

Metabolism. 2002 Mar;51(3):314-7.PMID: 11887166 [PubMed - indexed for MEDLINE]Related articles

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

Martens FM, Visseren FL, de Koning EJ, Rabelink TJ.

J Cardiovasc Pharmacol. 2005 Dec;46(6):773-8.PMID: 16306801 [PubMed - indexed for MEDLINE]Related articles

Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.

Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI.

Metabolism. 2004 Nov;53(11):1454-61.PMID: 15536601 [PubMed - indexed for MEDLINE]Related articles

Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.

Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P.

Clin Endocrinol (Oxf). 2006 Dec;65(6):722-8.PMID: 17121522 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.

Coletta DK, Sriwijitkamol A, Wajcberg E, Tantiwong P, Li M, Prentki M, Madiraju M, Jenkinson CP, Cersosimo E, Musi N, Defronzo RA.

Diabetologia. 2009 Apr;52(4):723-32. Epub 2009 Jan 24.PMID: 19169664 [PubMed - indexed for MEDLINE]Related articles

Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones.

Oz O, Tuncel E, Eryilmaz S, Fazlioglu M, Gul CB, Ersoy C, Ocak N, Dirican M, Cangur S, Baran I, Imamoglu S.

Endocrine. 2008 Feb;33(1):101-5. Epub 2008 Apr 5.PMID: 18392690 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.

Tan M, Johns D, González Gálvez G, Antúnez O, Fabián G, Flores-Lozano F, Zúñiga Guajardo S, Garza E, Morales H, Konkoy C, Herz M; GLAD Study Group.

Clin Ther. 2004 May;26(5):680-93.PMID: 15220012 [PubMed - indexed for MEDLINE]Related articles

A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.

Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T.

Diabetes Care. 2006 Jan;29(1):101-6.PMID: 16373904 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients.

Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K, Koide H.

Metabolism. 2004 Oct;53(10):1382-6.PMID: 15375799 [PubMed - indexed for MEDLINE]Related articles

The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin.

Tooke JE, Elston LM, Gooding KM, Ball CI, Mawson DM, Piper J, Sriraman R, Urquhart R, Shore AC.

Diabetologia. 2006 May;49(5):1064-70. Epub 2006 Mar 1.PMID: 16508777 [PubMed - indexed for MEDLINE]Related articles